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Functional Class (WHO FC). The algorithm, when 
used in a group of patients suspected for PH, dis‑
criminated well between those with PH and those 
without, with the positive and negative predictive 
values of 93% and 96%, respectively.
Several ECG abnormalities, including an in‑
crease in the P ‑wave amplitude in lead II, P ‑wave 
duration, resting heart rate, precordial electrocar‑
diogram voltage (sum of the R ‑wave amplitude in 
lead V1 and maximum S ‑wave amplitude in lead 
V5 or V6), QRS, and QTc duration and the pres‑
ence of qR in lead V1 were shown to impact prog‑
nosis of patients with PAH or CTEPH.6 Impor‑
tantly, the number of ECG abnormalities increas‑
es with the progression of PH, as shown recently 
by Tonelli et al.7 They compared ECG of patients 
with PAH at the time of diagnosis and at the time 
close to death and observed that close to death 
there was an increase in heart rate, PR interval 
length, QRS duration, QTc duration, R/S ampli‑
tude ratio in lead V1 as well as rightward rota‑
tion of QRS axis and more common occurrence of 
right bundle ‑branch block and negative T waves 
in inferior leads. They found that at the time of 
death, all patients with PAH had abnormal ECG.
In the last decades, advances in the treatment 
of PAH and CTEPH1,8 allowed several groups to 
show significant improvement in pulmonary he‑
modynamics, which resulted in reverse remodel‑
ing of the right heart chambers. The use of high 
doses of epoprostenol combined with endothelin 
receptor antagonists and phosphodiesterase ‑5 in‑
hibitors early after diagnosis of PAH resulted in 
a significant drop in mean pulmonary artery pres‑
sure in several reports, mostly in the Japanese 
population, but also in Polish patients.9 These 
hemodynamic effects resulted in improvement 
of several ECG parameters including the R ‑wave 
amplitude in lead V1, QRS axis, S ‑wave ampli‑
tude in lead V1, R/S amplitude in lead V6, ventric‑
ular activation time and right ventricular strain 
in leads V2 through V4.
10 Importantly, Japanese 
patients in whom the R ‑wave amplitude in lead 
Chronic thromboembolic pulmonary hyperten‑
sion (CTEPH) is a severe chronic disease caused 
by obstruction of pulmonary arteries by organized 
thrombi accompanied by microvascular remodel‑
ing.1 Elevated pulmonary artery pressure leads to 
enlargement of the right ventricle and right atri‑
um which can be reflected by several electrocar‑
diographic (ECG) parameters. Despite the rapid 
development of advanced diagnostic methods, 
ECG continuously attracts the attention of car‑
diovascular research groups because it is a widely 
used, easily available, inexpensive, and noninva‑
sive diagnostic tool included in the medical cur‑
riculum.2 In 2009, the American Heart Associa‑
tion, the American College of Cardiology Foun‑
dation, and the Heart Rhythm Society proposed 
24 criteria for ECG diagnosis of right ventricular 
hypertrophy which were based mainly on histo‑
logical studies of the heart. The clinical utility of 
these criteria were further evaluated by several 
groups, usually in patients with precapillary pul‑
monary hypertension (PH).3 Accordingly, ECG 
was tested as a tool to screen for PH, to deter‑
mine prognosis of patients with established PH, 
and to monitor treatment outcomes.
ECG is currently recommended as an addition‑
al diagnostic tool in PH, giving priority to echo‑
cardiography in screening for PH and to the right 
heart catheterization in diagnosing PH. Howev‑
er, despite a relatively low sensitivity and spec‑
ificity, ECG is still useful at an early stage of PH 
diagnostic workup. Sawada et al4 demonstrated 
that a school ECG ‑based mass screening program 
in the general Japanese pediatric population al‑
lowed diagnosis of pulmonary arterial hyperten‑
sion (PAH) at an early asymptomatic phase. In an‑
other study, Kovacs et al5 showed that ECG ac‑
curacy to screen for PH may be substantially im‑
proved by combining it with other noninvasive 
tests. They proposed a 2 ‑step algorithm based on 
ECG (right axis deviation), N ‑terminal pro ‑B‑type 
natriuretic peptide (NT ‑proBNP) level, arterial ox‑
ygen saturation, and World Health Organization 
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V1 decreased had better survival than other pa‑
tients. Survival benefit of the R ‑wave amplitude 
reduction in lead V1 was also documented by Pol‑
ish authors in a group of 80 patients with PAH 
and CTEPH.11
Recent advances in interventional treatment 
of inoperable CTEPH patients by balloon pulmo‑
nary angioplasty (BPA) resulted in excellent he‑
modynamic effects.1 In this issue of the Polish Ar-
chives of Internal Medicine (Pol Arch Intern Med), 
Piłka et al12 analyzed changes in ECG markers of 
right ventricular hypertrophy in a large group (n 
= 41) of patients with inoperable CTEPH treat‑
ed with BPA. They showed that a change of pul‑
monary vascular resistance after BPA correlates 
with changes of the axis of QRS complex and 
T waves, R/S amplitude ratio in lead V5, and am‑
plitudes of the following waves: P in lead II and 
III, S in leads V5, V6, and I. The hemodynamic ef‑
fect of their treatment was remarkable (change of 
median mean pulmonary arterial pressure from 
50 mm Hg to 27 mm Hg) which resulted in an‑
ticipated ECG improvement. In this way, the au‑
thors confirmed the results of previously pub‑
lished studies.13,14 The paper also provides nov‑
el and clinically useful data comparing changes 
of several ECG parameters in relation to the he‑
modynamic effect of BPA. Based on these data, it 
might be suspected that the T ‑wave axis, P ‑wave 
amplitude in lead II, and R ‑wave amplitude in lead 
V6 are very sensitive to pulmonary vascular re‑
sistance reduction. On the other hand, improve‑
ments in the other ECG parameters (QRS axis, 
S ‑wave amplitude in V5, R/S ratio in lead V5, ST ‑T 
segment depression or negative T waves in leads 
V1 throug V3 or more precordial leads, and neg‑
ative T waves in leads II, III, aVF) might predict 
a significant hemodynamic improvement after 
BPA. An additional, prospective study would be 
needed to validate these findings. However, there 
still remains a question whether these ECG data 
give us any more information about BPA effective‑
ness than those based on symptoms, NT ‑proBNP 
level, and echocardiography. It is also crucial to 
understand the pathophysiology of the particular 
ECG changes. Asano et al15 in their recent study 
showed that prolonged QRS duration together 
with older age predict poor recovery of the RV 
function after BPA despite good hemodynam‑
ic results. They also showed that QRS duration 
correlated with the area of fibrosis in the right 
ventricle.
While Piłka et al12 are to be congratulated on 
their interesting paper, there still are several im‑
portant questions about the role of ECG monitor‑
ing in patients with CTEPH treated with BPA to be 
answered. These include its prognostic impact in 
terms of physical fitness, the risk of hospitaliza‑
tion, and survival. A large cohort and multicenter 
approach are required to answer this question.
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